Jiten Patel, MD
Pulmonary Disease · Spokane, WANPI 1689895211
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $156,462 of the $200,157 with a category attached, or 78.2%. Boehringer Ingelheim accounts for 62.8% of it on its own, with 35 other manufacturers making up the rest. Among pulmonary disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 659 payments — averaging $303.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$126K
- Actelion Pharmaceuticals US, Inc.$49K
- United Therapeutics Corporation$9K
- Intuitive Surgical$6K
- AstraZeneca$2K
- GSK$1K
- plus $7K from 30 others
Across 38 payments — averaging $5150.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$78K
- Concordia Laboratories Inc.$38K
- Bayer$34K
- Actelion Pharmaceuticals, Ltd$19K
- United Therapeutics Corporation$18K
- Actelion Pharmaceuticals US, Inc.$10K
What the payments were for
- Consulting fees$6,5503%
- Speaking & faculty fees$156,46278%
- Travel & lodging$20,16110%
- Food & beverage$13,7237%
- Education$3,2612%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 139 | $125,781 |
| Actelion Pharmaceuticals US, Inc. | 80 | $48,618 |
| United Therapeutics Corporation | 52 | $9,191 |
| Intuitive Surgical | 22 | $6,392 |
| AstraZeneca | 72 | $1,807 |
| GSK | 145 | $1,482 |
| Steris Corporation | 5 | $1,438 |
| Pulmonx Corporation | 5 | $1,313 |
| Electromed, Inc. | 19 | $694 |
| Grifols USA, LLC | 9 | $325 |
| Boston Scientific | 4 | $272 |
| Regeneron Healthcare Solutions, Inc. | 9 | $258 |
| Insmed, Inc. | 6 | $250 |
| Sanofi | 11 | $243 |
| Merck | 7 | $197 |
| Sanofi-aventis U.S. LLC | 3 | $186 |
| Mylan Specialty L.p. | 10 | $183 |
| Baxter Healthcare | 7 | $175 |
| Genentech USA, Inc. | 9 | $173 |
| Galvanize Therapeutics, Inc | 1 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $134 |
| Philips North America LLC | 7 | $126 |
| Amgen | 6 | $124 |
| Johnson & Johnson | 1 | $122 |
| Advanced Respiratory, Inc | 6 | $116 |
| Verona Pharma, Inc. | 4 | $87 |
| Pinnacle Biologics, Inc | 4 | $85 |
| Pfizer | 1 | $62 |
| Gilead | 2 | $41 |
| Novartis | 1 | $33 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| Covidien LP | 1 | $18 |
| Viatris Specialty LLC | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Medtronic | 1 | $12 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$77,314
- UPTRAVI$47,458
- OPSUMIT$47,458
- TYVASO$7,786
- Da Vinci Surgical System$6,043
- TRUFREEZE$1,323
- Pulmonx Endobronchial Valve EBV$1,169
- FASENRA$423
- TEZSPIRE$423
- BREZTRI$319
- SYMBICORT$319
- AIRSUPRA$245
- Prolastin-C Liquid$152
- GENERAL PULMONARY$147
- ALIYA SYSTEM$145
- CHARTIS CATHETER$137
- ZEPHYR DELIVERY CATHETER$137
- ZEPHYR ENDOBRONCHIAL VALVE$137
- PULMONX CHARTIS TABLET CONSOLE$137
- Monarch Platform$122
How this compares
$200,157 in reported general payments places this provider in the 95th percentile of 275 pulmonary disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 79 | $1,817,448 |
| OpsumitMacitentan | 59 | $744,320 |
| AdempasRiociguat | 42 | $588,219 |
| OfevNintedanib Esylate | 37 | $475,837 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 498 | $277,798 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 248 | $210,108 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 178 | $103,080 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 153 | $96,655 |
| Spiriva RespimatTiotropium Bromide | 61 | $34,782 |
| Breo ElliptaFluticasone/Vilanterol | 50 | $32,642 |
| Arnuity ElliptaFluticasone Furoate | 80 | $25,149 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 38 | $17,993 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $11,358 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 241 | $7,520 |
| Roflumilast | 127 | $7,003 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $125,781 | $788,418596 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $48,618 | $744,32059 claims |
| BayerAdempas | $12 | $588,21942 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,482 | $374,874567 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $1,807 | $126,005218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 275 pulmonary disease providers in Washington.
Other pulmonary disease in Spokane
- Griffith LiangSpokane$13K
- Fatima AjazSpokane$6K
- Benjamin ArthursSpokane$6K
- Harshwant GroverSpokane$6K
- Bryan AndersonSpokane$4K
- Jed GordenSeattle$236K
- Dominique PepperOlympia$212K
- Oneil BainsSeattle$156K
- Ganesh RaghuSeattle$147K
- Nicholas WyshamVancouver$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.